

## **Adult Thoracic - Lung Transplant Recipient Registration Worksheet**

FORM APPROVED: O.M.B. NO. 0915-0157 Expiration Date: 12/31/2011

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI® application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI® application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Name:	DOB:
SSN:	Gender:
HIC:	Tx Date:
State of Permanent Residence: ★	
Permanent Zip: **	
Recipient Center:	
Physician Name: **	
Physician NPI#: *	
Surgeon Name: *	
Surgeon NPI#: ★	
UNOS Donor ID #:	
Donor Type:	
Primary Diagnosis: *	
Specify:	
Date: Last Seen, Retransplanted or Death **	
	C LIVING
Patient Status: *	C DEAD
	C RETRANSPLANTED

Primary Cause of Death:	
Specify:	
Contributory Cause of Death:	
Specify:	
Contributory Cause of Death:  Specify:	
Transplant Hospitalization:	
Date of Admission to Tx Center: ★	
Date of Discharge from Tx Center:	
Was patient hospitalized during the last 90 days prior to the transplant admission:	C YES C NO C UNK
	IN INTENSIVE CARE UNIT
Medical Condition: ★	C HOSPITALIZED NOT IN ICU
	NOT HOSPITALIZED
Patient on Life Support: *	C YES NO
	Extra Corporeal Membrane Oxygenation
	Intra Aortic Balloon Pump
	Prostacyclin Infusion
	Prostacyclin Inhalation
	Inhaled NO
	Ventilator
	Other Mechanism

Specify:	
Functional Status: *	
Physical Capacity:	No Limitations  Limited Mobility  Wheelchair bound or more limited  Not Applicable (< 1 year old or hospitalized)  Unknown
Working for income: ★	O YES O NO UNK
If No, Not Working Due To:	
If Yes:	Working Full Time  Working Part Time due to Demands of Treatment  Working Part Time due to Disability  Working Part Time due to Insurance Conflict  Working Part Time due to Inability to Find Full Time Work  Working Part Time due to Patient Choice  Working Part Time Reason Unknown  Working, Part Time vs. Full Time Unknown
Academic Progress:	Within One Grade Level of Peers  Delayed Grade Level  Special Education  Not Applicable < 5 years old/ High School graduate or GED  Status Unknown

0		e in academics due to disea ears old/ High School gradu	
0	Not Applicable < 5 ye		
		ears old/ High School gradu	uate or GED
°	Status Unknown		
	], [		0.7
	Tt. III.	cm	ST=
	lbs	kg	ST=
kg/m <sup>-</sup>			
Previous Transplant I	Date	Previous Transplant G	raft Fail Date
ed here. Please contact the nos.org.	UNet Help Desk to co	onfirm more than three prev	ious transplants by calling 800
0	Positive		
0	Negative		
0	Not Done		
0	UNK/Cannot Disclos	e	
0	Positive		
	contact the nos.org.	Previous Transplant Date  ad here. Please contact the UNet Help Desk to conso.org.  Positive Negative Not Done UNK/Cannot Disclos	Previous Transplant Date  Previous Transplant G  ad here. Please contact the UNet Help Desk to confirm more than three previous.org.  Positive  Negative  Not Done  UNK/Cannot Disclose

	0	Not Done
	0	UNK/Cannot Disclose
	0	Positive
CMV IgM: ★	0	Negative
	0	Not Done
	0	UNK/Cannot Disclose
	0	Positive
HBV Core Antibody: ★	0	Negative
TIBV GOTE ATTRIBUTY.	0	Not Done
	0	UNK/Cannot Disclose
	0	Positive
HBV Surface Antigen: ★	0	Negative
	0	Not Done
	0	UNK/Cannot Disclose
	0	Positive
HCV Serostatus: ★	0	Negative
	0	Not Done
	0	UNK/Cannot Disclose
	0	Positive
EBV Serostatus: *	0	Negative
	0	Not Done
	0	UNK/Cannot Disclose
Most Recent Hemodynamics:		Inotropes/Vasodilators:
PA (sys)mm/Hg: *		ST= C YES NO

PA(dia) mm/Hg: *		ST=	YES NO
PA(mean) mm/Hg: ★		ST=	C YES C NO
PCW(mean) mm/Hg: *		ST=	C YES C NO
CO L/min: *		ST=	C YES C NO
Most Recent Serum Creatinine: ★	mg/dl	ST=	
Most Recent Total Bilirubin: *	mg/dl	ST=	
Oxygen Requirement at Rest:	L/min	ST=	
Chronic Steroid Use: **	C YES C NO C UNK		
Pulmonary Status (Give most recent value):			
FVC: *	%predicted:	ST=	
FeV1: *	%predicted:	ST=	
pCO2: **	mm/Hg:	ST=	
Events occurring between listing and transplant:			
Transfusions: ★	O YES O NO UNK		
Pulmonary Embolism:	O YES O NO UNK		
Infection Requiring IV Therapy within 2 wks prior to Tx: *	C YES C NO UNK		
Cerebrovascular Event:	O YES O NO UNK		
Dialysis: *	C YES C NO C UNK		
Implantable Defibrillator:	C YES C NO UNK		
Prior Cardiac Surgery (non-transplant): ★	C YES O NO UNK		
If yes, check all that apply:			

	Valve Replacement/Repair
	Congenital
	Left Ventricular Remodeling
	Other, specify
Specify:	
Prior Lung Surgery (non-transplant): ★	C YES C NO UNK
	Pneumoreduction
	Pneumothorax Surgery-Nodule
	Pneumothorax Decortication
If you about all that apply	Lobectomy
If yes, check all that apply:	Pneumonectomy
	Left Thoracotomy
	Right Thoracotomy
	Other, specify
Specify:	
Episode of Ventilatory Support: **	C YES C NO C UNK
	At time of transplant
If yes, indicate most recent timeframe:	Within 3 months of transplant
	>3 months prior to transplant
Tracheostomy: *	C YES C NO C UNK
	С
	NO PREVIOUS PREGNANCY
Previous Pregnancies:	1 PREVIOUS PREGNANCY
	2 PREVIOUS PREGNANCIES

	0	3 PREVIOUS PREGNANCIES
	0	4 PREVIOUS PREGNANCIES
	0	5 PREVIOUS PREGNANCIES
	0	MORE THAN 5 PREVIOUS PREGNANCIES
	0	
	0	NOT APPLICABLE: < 10 years old
		UNKNOWN
Malignancies between listing and transplant: *	0	YES NO UNK
This question is NOT applicable for patients receiving living d	onor tra	ansplants who were never on the waiting list.
		Skin Melanoma
		Skin Non-Melanoma
		CNS Tumor
		Genitourinary
		Breast
If yes, specify type:		Thyroid
		Tongue/Throat/Larynx
		Lung
	П	Leukemia/Lymphoma
	П	Liver
		Other, specify
Specify:		
1		
Multiple Organ Recipient		
Ware outra vessels used in the transplant precedure:		
Were extra vessels used in the transplant procedure:  Vessel Donor ID:		

	SINGLE LEFT LUNG
	SINGLE RIGHT LUNG
Procedure Type:	© BILATERAL SEQUENTIAL LUNG
	EN-BLOC DOUBLE LUNG
	C LOBE, RIGHT
	C LOBE, LEFT
Was this a retransplant due to failure of a previous thoracic graft:	C <sub>YES</sub> C <sub>NO</sub>
Total Organ Ischemia Time (include cold, warm and anas	stomotic time):
Left Lung:	min ST=
Right Lung (OR EN-BLOC):	min ST=
Incidental Tumor found at time of Transplant:	C YES C NO UNK
	C Adenoma
	Carcinoma
If yes, specify tumor type:	Carcinoid
	Lymphoma
	C Harmartoma
	Other Primary Lung Tumor, Specify
Specify:	
Graft Status: ★	C Functioning C Failed
If death is indicated for the recipient, and the death was a res Date of Graft Failure:	sult of some other factor unrelated to graft failure, select Functioning.
Date of Statt Latitute.	

	О	Primary Non-Function
Primary Cause of Graft Failure:	0	Acute Rejection
Timaly dauge of Grant andre.	О	Chronic Rejection/Atherosclerosis
	0	Other, Specify
Specify:		
Events Prior to Discharge:		
Any Drug Treated Infection:	0	YES O NO UNK
Stroke: *	0	YES NO UNK
Dialysis: *	0	YES NO UNK
Cardiac Re-Operation:	0	YES NO UNK
Other Surgical Procedures:	0	YES NO UNK
	0	No
	0	Ventilator support for <= 48 hours
Ventilator Support: ★	0	Ventilator support for >48 hours but < 5 days
ventilator Support.	0	Ventilator support >= 5 days
	0	Ventilator support, duration unknown
	0	Unknown Status
Reintubated: *	0	YES NO UNK
Permanent Pacemaker: ★	0	YES O NO UNK
Chest drain >2 weeks:	0	YES O NO UNK
Airway Dehiscence: *	0	YES O NO UNK

	O	Yes, at least one episode treated with anti-rejection agent
Did patient have any acute rejection episodes between transplant and discharge:   ★	0	Yes, none treated with additional anti-rejection agent
	0	No
	0	Biopsy not done
Was biopsy done to confirm acute rejection:	0	Yes, rejection confirmed
	0	Yes, rejection not confirmed
Biological or Anti-viral Therapy:	0	YES NO Unknown/Cannot disclose
		Acyclovir (Zovirax)
		Cytogam (CMV)
		Gamimune
		Gammagard
		Ganciclovir (Cytovene)
If Yes, check all that apply:		Valgancyclovir (Valcyte)
		HBIG (Hepatitis B Immune Globulin)
		Flu Vaccine (Influenza Virus)
		Lamivudine (Epivir) (for treatment of Hepatitis B)
		Other, Specify
		Valacyclovir (Valtrex)
Specify:		
Specify:		
	0	
Other therapies:	•	YES NO

		Photopheresis
If Yes, check all that apply:		Plasmapheresis
		Total Lymphoid Irradiation (TLI)
Are any medications given currently for maintenance or anti-rejection: **	0	YES NO
Did the patient participate in any clinical research protocol for immunosuppressive medications:	0	YES NO
If Yes, Specify:		
View Immunosuppressive Medications		
Definitions Of Immunosuppressive Medications		

For each of the immunosuppressant medications listed, check **Previous Maintenance (Prev Maint)**, **Current Maintenance (Curr Maint)** or **Antirejection (AR)** to indicate all medications that were prescribed for the recipient during this follow-up period, and for what reason. If a medication was not given, leave the associated box(es) blank.

Previous Maintenance (Prev Maint) includes all immunosuppressive medications given during the report period, which covers the period from the last clinic visit to the current clinic visit, for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes.

Current Maintenance (Curr Maint) includes all immunosuppressive medications given at the current clinic visit to begin in the next report for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes.

Anti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode since the last clinic visit (example: Methylprednisolone, Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs (example: from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of rejection, the drugs should not be listed under AR immunosuppression, but should be listed under maintenance immunosuppression.

Note: The Anti-rejection field refers to any anti-rejection medications since the last clinic visit, not just at the time of the current clinic visit.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select Previous Maint, or Current Maint, or AR next to Other Immunosuppressive Medication field, and enter the full name of the medication in the space provided. <u>Do not list non-immunosuppressive medications.</u>

For each of the immunosuppressive medications listed, select Ind (Induction), Maint (Maintenance) or AR (Anti-rejection) to indicate all medications that were prescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box(es) blank.

Induction (Ind) immunosuppression includes all medications given for a short finite period in the perioperative period for the purpose of preventing acute rejection. Though the drugs may be continued after discharge for the first 30 days after transplant, it will not be used long-term for immunosuppressive maintenance. Induction agents are usually polyclonal, monoclonal, or IL-2 receptor antibodies (example: Methylprednisolone, Atgam, Thymoglobulin, OKT3, Simulect, or Zenapax). Some of these drugs might be used for another finite period for rejection therapy and would be recorded as rejection therapy if used for this reason. For each induction medication indicated, write the total number of days the drug was actually administered in the space provided. For example, if Simulect or Zenapax was given in 2 doses a week apart, then the total number of days would be 2, even if the second dose was given after the patient was discharged.

Maintenance (Maint) includes all immunosuppressive medications given before, during or after transplant for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes, or for induction.

Anti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode during the initial post-transplant period or during a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (example:

Methylprednisolone, Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs (example: from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of rejection, the drugs should not be listed under AR immunosuppression, but should be listed under maintenance immunosuppression.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select Ind, Maint, or AR next to Other Immunosuppressive Medication field, and enter the full name of the medication in the space provided. **Do not list non-immunosuppressive** medications.

Steroids (Prednisone,Methylprednisolone,Solumedrol,Medrol,Decadron)	Ind.	Days	ST	Maint	AR
Atgam (ATG)					
OKT3 (Orthoclone, Muromonab)					
Thymoglobulin					
Simulect - Basiliximab					
Zenapax - Daclizumab					
Azathioprine (AZA, Imuran)					
EON (Generic Cyclosporine)					
Gengraf (Abbott Cyclosporine)					
Other generic Cyclosporine, specify brand:					
Neoral (CyA-NOF)					
Sandimmune (Cyclosporine A)					
CellCept (Mycophenolate Mofetil; MMF)					
Generic MMF (Generic CellCept)					
Prograf (Tacrolimus, FK506)					
Generic Tacrolimus (Generic Prograf)					
Advagraf (Tacrolimus Extended or Modified Release)					
Nulojix (Belatacept)					

Sirolimus (RAPA, Rapamycin, Rapamune)			_		
Myfortic (Mycophenolate Sodium)	I				
Campath - Alemtuzumab (anti-CD52)	Ind.	Days	ST	Maint	AR
Cyclophosphamide (Cytoxan)					
Leflunomide (LFL, Arava)					
Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)					
Other Immunosuppressive Medication, Specify					
Rituximab					
	Ind.	Days	ST	Maint	AR
Zortress (Everolimus)					
Other Immunosuppressive Medication, Specify					

С